Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2017

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	Fiscal Year Ended June 30,
Medical Indication	2017			2016			2015
Antibiotic	$	16,748		$	14,558		$	12,306
Anti-Psychosis	58,625			5,462			2,260
Cardiovascular	50,628			53,541			55,166
Central Nervous System	39,451			36,291			—
Gallstone	48,600			67,348			65,262
Gastrointestinal	71,887			52,699			—
Glaucoma	18,763			25,336			21,145
Migraine	29,014			21,776			25,729
Muscle Relaxant	13,636			5,403			8,779
Obesity	3,956			3,809			4,004
Pain Management	26,135			29,804			27,461
Respiratory	10,516			9,982			—
Thyroid Deficiency	174,005			162,411			153,460
Urinary	14,695			17,398			212
Other	43,240			38,230			31,053
Contract manufacturing revenue	17,442			22,043			—
Net sales	637,341			566,091			406,837
Settlement agreement	(4,000		)	(23,598		)	—
Total net sales	$	633,341		$	542,493		$	406,837

Summary of products which accounted for at least 10% of total net sales

	June 30, 2017		June 30, 2016		June 30, 2015
Product 1	27	%	30	%	38	%
Product 2	8	%	12	%	16	%
Product 3	2	%	4	%	12	%

Summary of customers which accounted for at least 10% of total net sales

	June 30, 2017		June 30, 2016		June 30, 2015
Customer A	28	%	25	%	30	%
Customer B	21	%	16	%	11	%